<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759341</url>
  </required_header>
  <id_info>
    <org_study_id>CE 3015</org_study_id>
    <secondary_id>2016-00015</secondary_id>
    <nct_id>NCT02759341</nct_id>
  </id_info>
  <brief_title>Brain-heart Interactions in Tako-Tsubo Cardiomyopathy and Cardiac Syndrome X:</brief_title>
  <acronym>BRAINHEART</acronym>
  <official_title>Tako-Tsubo Cardiomyopathy and Cardiac Syndrome X: a Study on the Brain-heart Interactions in Two Orphan Cardiac Diseases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Giovanni Bellinzona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale San Giovanni Bellinzona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Tako-Tsubo Cardiomyopathy (TTC) and the Cardiac Syndrome X (CSX) are respectively acute
      and chronic heart diseases, which mimic myocardial infarction and stable angina pectoris
      without alterations of large coronary vessels. The causes and the most appropriate and best
      treatment for these diseases have not been yet clarified, but there are indications, that
      mental and psychosocial aspects may also contribute to these two diseases. So far, there is
      no study, which has comprehensively evaluated the interactions between mind and heart in
      these two conditions.

      The purpose of this study is to search for possible differences in mental activity, response
      to stressful events and function of specific areas of the brain deeply involved in relation
      between mind and heart.

      45 subjects will be recruited and divided equally into: patients with CSX, patients with TTC
      (at least 6 months ago) and patients with previous acute myocardial infarction (at least 6
      months ago). All participants will undergo a clinical interview and several questionnaires
      that assess various mental functions, the stress response and the quality of life. In
      addition, in a separate visit the participants will undergo a Magnetic Resonance Imaging
      without contrast medium that helps to assess function of specific areas of the brain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in BOLD-fMRI intensity signal in CSX and TTC as compared to AMI patients</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in BOLD-fMRI distribution signal in CSX and TTC as compared to AMI patients</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in CSX and TTC AMDP 8 results as compared to AMI patients</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in CSX and TTC MCMI-III results as compared to AMI patients</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in CSX and TTC STAI-Y results as compared to AMI patients</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in CSX and TTC SF-36 HRQOL results as compared to AMI patients</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Takotsubo Cardiomyopathy</condition>
  <condition>Cardiac X Syndrome</condition>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Cardiac X Syndrome (CSX)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Takotsubo Cardiomyopathy (TTC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute myocardial infarction (AMI)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Manual for the Assessment and Documentation of Psychopathology (AMDP 8)</intervention_name>
    <arm_group_label>Cardiac X Syndrome (CSX)</arm_group_label>
    <arm_group_label>Takotsubo Cardiomyopathy (TTC)</arm_group_label>
    <arm_group_label>Acute myocardial infarction (AMI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Million Clinical Multiaxial Inventory 3 (MCMI-III)</intervention_name>
    <arm_group_label>Cardiac X Syndrome (CSX)</arm_group_label>
    <arm_group_label>Takotsubo Cardiomyopathy (TTC)</arm_group_label>
    <arm_group_label>Acute myocardial infarction (AMI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>State-Trait Anxiety Inventory form Y (STAI-Y)</intervention_name>
    <arm_group_label>Cardiac X Syndrome (CSX)</arm_group_label>
    <arm_group_label>Takotsubo Cardiomyopathy (TTC)</arm_group_label>
    <arm_group_label>Acute myocardial infarction (AMI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SF-36 Health-Related Quality of Life</intervention_name>
    <arm_group_label>Cardiac X Syndrome (CSX)</arm_group_label>
    <arm_group_label>Takotsubo Cardiomyopathy (TTC)</arm_group_label>
    <arm_group_label>Acute myocardial infarction (AMI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)</intervention_name>
    <arm_group_label>Cardiac X Syndrome (CSX)</arm_group_label>
    <arm_group_label>Takotsubo Cardiomyopathy (TTC)</arm_group_label>
    <arm_group_label>Acute myocardial infarction (AMI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group A. 15 patients with Cardiac X Syndrome (CSX), according to the diagnostic
             criteria previously proposed by Lanza et al.

          -  Group B. 15 patients with Tako-Tsubo Cardiomyopathy (TTC), according to Mayo
             diagnostic criteria at least 6 months after being hospitalized or diagnosed with TTC.

          -  Group C (control group). 15 prospectively enrolled patients with previous Type 1, 4a,
             4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and
             Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome
             [ACS] with significant ≥70% coronary stenosis) at least six months after the event.

        Acute myocardial infarction will be defined according to the third universal definition of
        myocardial infarction.

        Exclusion Criteria:

          -  Refused consent

          -  Unable to participate or provide written informed consent

          -  Short-term survival (&lt;1 year)

          -  Acute or decompensated medical conditions

          -  Acute neurological or psychiatric diseases

          -  Absence of sinus rhythm or frequent ectopic beats

          -  History of severe lung, liver, kidney or autoimmune diseases

          -  Any contraindication to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mattia Cattaneo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Giovanni Bellinzona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Augusto Gallino, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale San Giovanni Bellinzona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Regionale di Bellinzona e Valli - Ospedale San Giovanni Bellinzona</name>
      <address>
        <city>Bellinzona</city>
        <state>Canton Ticino</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Lanza GA. Cardiac syndrome X: a critical overview and future perspectives. Heart. 2007 Feb;93(2):159-66. Epub 2006 Jan 6. Review.</citation>
    <PMID>16399854</PMID>
  </reference>
  <reference>
    <citation>Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008 Mar;155(3):408-17. doi: 10.1016/j.ahj.2007.11.008. Epub 2008 Jan 31. Review.</citation>
    <PMID>18294473</PMID>
  </reference>
  <reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct;33(20):2551-67. doi: 10.1093/eurheartj/ehs184. Epub 2012 Aug 24.</citation>
    <PMID>22922414</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Giovanni Bellinzona</investigator_affiliation>
    <investigator_full_name>Mattia Cattaneo</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Takotsubo Cardiomyopathy</mesh_term>
    <mesh_term>Microvascular Angina</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

